Hansoh Pharmaceutical's Aumolertinib Receives EU Approval for Advanced NSCLC Treatment
核心洞察
Hansoh Pharmaceutical Group (搜索) received European Commission approval on February 12, 2026, for Aumolertinib Mesylate Tablets (搜索) (Aumseqa (搜索)®) as monotherapy for advanced NSCLC (搜索) patients with specific EGFR (搜索) mutations.
The EU approval covers first-line treatment for patients with EGFR (搜索) exon 19 deletions or exon 21 mutations and treatment for EGFR T790M (搜索) mutation-positive NSCLC (搜索) patients.
This marks a significant milestone for China's first original third-generation EGFR (搜索)-TKI, which now has five approved indications in China and expanding international presence.
Hansoh Pharmaceutical Group (搜索) has achieved a landmark regulatory milestone with the European Commission's approval of Aumolertinib Mesylate Tablets (搜索) (marketed as Aumseqa (搜索)® outside China) for advanced non-small cell lung cancer (NSCLC (搜索)) treatment. The approval, granted on February 12, 2026, follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Approved Indications and Clinical Applications
The European Commission approval encompasses two critical treatment scenarios for advanced NSCLC (搜索) patients. The drug is now authorized as first-line monotherapy for adult patients with advanced NSCLC whose tumors harbor EGFR (搜索) exon 19 deletions or exon 21 (L858R) substitution mutations. Additionally, it received approval for treating adult patients with advanced EGFR T790M (搜索) mutation-positive NSCLC.
Aumolertinib represents China's first original third-generation EGFR (搜索) tyrosine kinase inhibitor (EGFR-TKI), marking a significant achievement in domestic pharmaceutical innovation. The drug has demonstrated robust clinical efficacy across multiple patient populations, leading to its broad regulatory acceptance.
Comprehensive Regulatory Success in China
The Chinese National Medical Products Administration (NMPA) has approved five major indications for Aumolertinib (marketed as Ameile (搜索)® in China) since 2020. The initial approval in 2020 covered treatment of patients with locally advanced or metastatic NSCLC (搜索) with T790M (搜索) mutation who had progressed following EGFR (搜索)-TKI therapy.
In 2021, the drug gained first-line treatment approval for adult patients with locally advanced or metastatic NSCLC (搜索) whose tumors have EGFR (搜索) exon 19 deletions or exon 21 (L858R) substitution mutations. The regulatory expansion continued in 2025 with approval for treating patients with locally advanced, unresectable NSCLC whose disease had not progressed following definitive platinum-based chemoradiotherapy and whose tumors have specific EGFR mutations.
The NMPA also approved Aumolertinib in 2025 for adjuvant treatment of adult patients with stage II to IIIB NSCLC (搜索) whose tumors have EGFR (搜索) exon 19 deletions or exon 21 L858R mutations, following tumor resection with or without prior adjuvant chemotherapy. Most recently in 2026, Ameile (搜索) received approval in combination with pemetrexed and platinum-based chemotherapy as first-line treatment for adult patients with locally advanced or metastatic NSCLC with specific EGFR mutations.
International Market Expansion
Beyond the EU approval, Aumolertinib has gained international recognition through approval by the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) for marketing in 2025. This growing international acceptance signals the drug's potential for broader global market penetration.
The EU approval represents access to one of the world's largest and most lucrative pharmaceutical markets, positioning Hansoh for significant revenue growth and enhanced international presence. The multiple regulatory endorsements validate the quality and innovation of Hansoh's research and development pipeline.
Market Performance and Valuation Impact
Following recent regulatory successes, Hansoh Pharmaceutical Group (搜索) has demonstrated strong market performance with a 1-day share price return of 2.11% at HK$41.6. The company has achieved a year-to-date share price return of 14.16% and a substantial 1-year total shareholder return of 159.02%, indicating building momentum despite some shorter-term fluctuations.
The company's current valuation reflects investor optimism, with a price-to-earnings ratio of 47.2x, significantly above the Hong Kong Pharmaceuticals industry average of 13.4x and the peer group average of 23.1x. However, discounted cash flow analysis suggests the shares may be trading 21.5% below an estimated fair value of HK$53.01, indicating potential undervaluation despite the premium earnings multiple.
Corporate Leadership and Governance
The announcement was made by Hansoh Pharmaceutical Group (搜索)'s Board of Directors, chaired by Ms. Zhong Huijuan, supported by a team of experienced executive and independent non-executive directors. This leadership structure underscores the company's commitment to solid corporate governance as it expands its global footprint.
The EU approval positions Aumolertinib Mesylate Tablets (搜索) as a core growth driver for Hansoh's oncology franchise, with multiple approved indications spanning both monotherapy and combination therapy settings for various stages of NSCLC (搜索) treatment.